Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 20;7(1):354.
doi: 10.1186/s40425-019-0813-8.

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

Brian I Rini  1 , Dena Battle  2 , Robert A Figlin  3 , Daniel J George  4 , Hans Hammers  5 , Tom Hutson  6 , Eric Jonasch  7 , Richard W Joseph  8 , David F McDermott  9 , Robert J Motzer  10 , Sumanta K Pal  11 , Allan J Pantuck  12 , David I Quinn  13 , Virginia Seery  9 , Martin H Voss  10 , Christopher G Wood  7 , Laura S Wood  1 , Michael B Atkins  14
Affiliations

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

Brian I Rini et al. J Immunother Cancer. .

Abstract

The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as monotherapy in 2015 for aRCC after treatment with a VEGF-targeting agent. In April 2018, the combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, was approved for intermediate- and poor-risk, previously untreated patients with aRCC. Then, in 2019, combinations therapies consisting of pembrolizumab (anti-PD-1) or avelumab (anti-PD-ligand (L) 1) with axitinib (a VEGF receptor tyrosine kinase inhibitor) were also approved to treat aRCC and are likely to produce dramatic shifts in the therapeutic landscape. To address the rapid advances in immunotherapy options for patients with aRCC, the Society for Immunotherapy of Cancer (SITC) reconvened its Cancer Immunotherapy Guidelines (CIG) Renal Cell Carcinoma Subcommittee and tasked it with generating updated consensus recommendations for the treatment of patients with this disease.

Keywords: Guidelines; Immune checkpoint inhibitor (ICI); Immunotherapy; Kidney cancer; Renal cell carcinoma (RCC).

PubMed Disclaimer

Conflict of interest statement

MBA serves on the AB for BMS, Merck, Eisai, Novartis, Pfizer and Exelixis. BIR has served as consultant for BMS, Roche, Compugen, Novartis, Pfizer, Synthorx and Peloton; receives research funding from Pfizer, Merck, BMS, Roche and Peloton. RAF serves as consultant to Apolommics, Pfizer, BMS, and Eisai; receives research funding from Peloton, Exelixixs, Calithera, Merck, and BMS. DJG serves on the SAB for Capio Biosciences; receives research funding from Sanofi, Novartis, Pfizer, Janssen, Exelixis, Acerta, Dendreon, Calithera, BMS, Bayer; serves as consultant for Sanofi, Pfizer, Merck, Janssen, Genentech, Exelixis, BMS, Astellas, Bayer, AstraZeneca, Nektar; independent contractor for Axess Oncology; received honoraria from EMD Serono, Ipsen, OncLive and UroToday; steering committee for NCI, Nektar and Pfizer. HH receives advisory/consulting fees from BMS, Merck, Novartis, Pfizer, Exelxis, Armo Biosciences, Lilly, Corvus, and Eisai; clinical research support from BMS, Merck, and Exelixis. EJ serves as consultant for Eisai and Novartis; received research funding from Novartis, Exelixis, Pfizer and Peloton. RWJ serves as consultant and on the AB for BMS, Merck and Exelixis. DFM received honoraria for consulting with BMS, Pfizer, Merck, Novartis, Eisai, Exelixis, Array BioPharm and Genentech; received research funding from Prometheus and BMS. RJM served as consultant for Pfizer, Genentech/Roche, Merck, Novartis, Eisai and Exelixis; received research funding from Pfizer, Genentech/Roche, Bristol Myers Squibb, Novartis, and Eisai. SKP served as consultant for Genentech, Aveo, Aisai, Roche, Pfizer, Novartis, Exelixis, Ipsen, BMS and Astellas. AJP is an equity holder with Allogene and Urogen; served as consultant for Pfizer, founder of Equity and on BOD at Athos Therapeutics. MHV served as consultant for Corvus, Calithera, Pfizer, Eisai, Exelixis; received research grants from BMS and Pfizer. CGW served as advisor for Merck; received research funding from Argos, Pfizer and BMS; chairman, BOD and on the medical steering committee for the Kidney Cancer Association. LSW served on the speaker’s bureau at BMS, Merck, Pfizer and Genentech; served as consultant on nursing care for Eisai and EMD Serano. DB, TH, VS, and DIQ declare no competing interests.

Figures

Fig. 1
Fig. 1
Immunotherapy treatment algorithm for patients with advanced renal cell carcinoma
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Xu JX, et al. FDA approval summary: Nivolumab in advanced renal cell carcinoma after anti-Angiogenic therapy and exploratory predictive biomarker analysis. Oncologist. 2017;22(3):311–317. doi: 10.1634/theoncologist.2016-0476. - DOI - PMC - PubMed
    1. Rini BI, et al. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer. 2016;4:81. doi: 10.1186/s40425-016-0180-7. - DOI - PMC - PubMed
    1. Institute of Medicine (U.S.) Committee on standards for developing trustworthy clinical practice guidelines. In: Graham R, editor. Clinical practice guidelines we can trust. Washington, DC: National Academies Press; 2011. p. xxxiv. - PubMed
    1. Kaufman HL, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013;10(10):588–598. doi: 10.1038/nrclinonc.2013.153. - DOI - PubMed
    1. Hammers HJ, et al. Safety and efficacy of Nivolumab in combination with Ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J Clin Oncol. 2017;35(34):3851–3858. doi: 10.1200/JCO.2016.72.1985. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances